Bibliography
- Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182:11S-18S
- Opioids for persistent pain: good practice. The British Pain Society. 2010. Available from: http://www.britishpainsociety.org/book_opioid_main.pdf [Last accessed 24 January 2011]
- Moss J, Rosow CE. Development of peripheral opioid antagonists' new insights into opioid effects. Mayo Clin Proc 2008;83:1116-30
- Bell TJ, Panchal SJ, Miaskowski C, The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 2009;10:35-42
- Holzer P. Opioid antagonists for prevention and treatment of opioid-induced gastrointestinal effects. Curr Opin Anaesthesiol 2010;23:616-22
- Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007;61:1181-7
- Becker G, Blum HE. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. Lancet 2009;373:1198-206
- Thomas J. Opioid-induced bowel dysfunction. J Pain Symptom Manage 2008;35:103-13
- Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept 2009;155:11-17
- Herndon CM, Jackson KC, Hallin PA. Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy 2002;22:240-50
- Zeinali F, Stulberg JJ, Delaney CP. Pharmacological management of postoperative ileus. Can J Surg 2009;52:153-7
- Kraft MD. Methylnaltrexone, a new peripherally acting mu-opioid receptor antagonist being evaluated for the treatment of postoperative ileus. Expert Opin Investig Drugs 2008;17:1365-77
- Cherny N, Ripamonti C, Pereira J, Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001;19:2542-54
- Thomas JR, Von Gunten CF. Management of constipation in patients with cancer. Support Cancer Ther 2004;2:47-51
- Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002;23:48-53
- Sykes NP. Oral naloxone in opioid-associated constipation. Lancet 1991;337:1475
- Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 1996;10:135-44
- Lowenstein O, Leyendecker P, Hopp M, Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009;10:531-43
- Simpson K, Leyendecker P, Hopp M, Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008;24:3503-12
- Targinact – opioid pain relief without constipation? Drug Ther Bull 2010;48:138-41
- Meissner W, Leyendecker P, Mueller-Lissner S, A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13:56-64
- Berde C, Nurko S. Opioid side effects – mechanism-based therapy. N Engl J Med 2008;358:2400-2
- Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann Pharmacother 2007;41:984-93
- Slatkin N, Thomas J, Lipman AG, Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol 2009;7:39-46
- Thomas J, Karver S, Cooney GA, Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358:2332-43
- Duerden M, Weil A, Yu D, Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patient with chronic non-malignant pain: safety results in patients treated for 12 weeks. 2010 [ Last accessed 25 January 2011]
- Duerden M, Weil A, Yu D, Subcutaneous methylnaltrexone improves bowel movement frequency and quality in patients with chronic non-malignant pain and opioid induced constipation. 2010 [ Last accessed 25 January 2011]
- Weil A, Duerden M, Schulman S, Subcutaneous methylnaltrexone does not effect pain intensity and analgesic use in patients with chronic non-malignant pain and opioid-induced constipation. 2010 [ Last accessed 25 January 2011]
- Press Release: phase 3 Clinical Study of RELISTOR Presented at American Pain Society Meeting Showed Positive Activity for the Treatment of Opioid-Induced Constipation in Chronic,Non-Cancer Pain Patients. Progenics. 2009. Available from: http://files.shareholder.com/downloads/PGNX/1157406583x0x293031/473fa970-714f-40ad-966a-4787e022bd1c/PGNX_News_2009_5_7_Clinical_Trials.pdf [Last accessed 25 January 2011]
- Press release: Progenics Announces Clinical Completion of Subcutaneous Methylnaltrexone Safety Study in Chronic Non-Malignant Pain Patients. Progenics. 2010. Available from: http://www.progenics.com/releasedetail.cfm?ReleaseID=509468 [Last accessed 25 January 2011]
- Foss JF, Bass AS, Goldberg LI. Dose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogs. J Clin Pharmacol 1993;33:747-51
- Foss JF, Yuan CS, Roizen MF, Goldberg LI. Prevention of apomorphine- or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine. Cancer Chemother Pharmacol 1998;42:287-91
- Moerman I, Franck P, Camu F. Evaluation of methylnaltrexone for the reduction of postoperative vomiting and nausea incidences. Acta Anaesthesiol Belg 1995;46:127-32
- Relistor: summary of product characteristics. Wyeth. 2008. Available from: http://www.wyeth.com/content/showlabeling.asp?id=499 [Last accessed 16 December 2008]
- Press Release: progenics pharmaceuticals initiates oral methylnaltrexone phase 3 trial in patients with chronic non-cancer pain. Progenics. 2010. Available from: http://files.shareholder.com/downloads/PGNX/1096988938x0x401269/5b0cf1cd-299f-4b0b-b4a3-aaa29f97035a/PGNX_News_2010_9_8_Clinical_Trials.pdf [Last accessed 25 January 2011]
- Alvimopan: summary of product characteristics. Glaxo SmithKline. 2008. [Last accessed 25 January 2011]
- Coombe R, Schaefer M. National PBM Drug Monograph: Alvimopan (Entereg). 2009. Available from: www.pbm.va.gov [Last accessed 25 January 2011]
- Delaney CP, Weese JL, Hyman NH, Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum 2005;48:1114-25
- Delaney CP, Wolff BG, Viscusi ER, Alvimopan, for postoperative ileus following bowel resection: a pooled analysis of phase III studies. Ann Surg 2007;245:355-63
- Herzog TJ, Coleman RL, Guerrieri JP Jr, A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy. Am J Obstet Gynecol 2006;195:445-53
- Senagore AJ. Pathogenesis and clinical and economic consequences of postoperative ileus. Am J Health Syst Pharm 2007;64:S3-7
- Tan EK, Cornish J, Darzi AW, Tekkis PP. Meta-analysis: Alvimopan vs. placebo in the treatment of post-operative ileus. Aliment Pharmacol Ther 2007;25:47-57
- Viscusi ER, Goldstein S, Witkowski T, Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc 2006;20:64-70
- Wolff BG, Michelassi F, Gerkin TM, Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg 2004;240:728-34
- Wolff BG, Weese JL, Ludwig KA, Postoperative ileus-related morbidity profile in patients treated with alvimopan after bowel resection. J Am Coll Surg 2007;204:609-16
- Schmidt WK. Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surg 2001;182:27S-38S
- Paulson DM, Kennedy DT, Donovick RA, Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction a 21-day treatment-randomized clinical trial. J Pain 2005;6:184-92
- Webster L, Jansen JP, Peppin J, Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008;137:428-40
- Press release: Adolor Corporation Provides Update on R&D Programs. Adolor corporation. 2008. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=120919&p=irol-newsArticle&ID=1237524&highlight= [Last accessed 25 January 2011]
- Alvimopan (Entereg) Package Insert. 2011. Available from: http://www.entereg.com/images/documents/prescribing-information.pdf [Last accessed 25 January 2011]
- ClinicalTrials.gov. 2011. Available from: http://www.clinicaltrials.gov/ct2/results?term=alvimopan [Last accessed 4 January 2011]
- Gale S, Croasdell G. 28th Annual JPMorgan Healthcare Conference–Exelixis and Nektar Therapeutics. IDrugs 2010;13:139-41
- Nektar corporation website. 2009. Available from: http://www.nektar.com/product_pipeline/clinical_trials.html [Last accessed 25 March 2009]
- Neumann TA, Van Paaschen H, Marcantonio A, Clinical investigation of NKTR-118 as a selective oral peripheral opioid antagonist. 2007. Available from: http://www.nektar.com/pdf/pipeline/NKTR-118/nktr-118_aapm_2007_clinical_data_poster_27.pdf [Last accessed 27 September 2007]
- Neumann TA, Van Paaschen H, Marcantonio A, Evaluation of PEG-Naloxol (NKTR-118) as an oral peripheral opioid antagonist in healthy male subjects: a Double-Blind, Placebo-Controlled, Dose Escalation Crossover Study. 2011. Available from: http://www.nektar.com/pdf/pipeline/NKTR-118/NKTR-118_aacp2007_single-dose_phase_1_trial.pdf [Last accessed 9 September 2007]
- Results from a phase 1, double blind, randomized, placebo-controlled, multiple-dose study evaluating the safety, tolerability and pharmacokinetics of oral doses of NKTR-118. Van Paaschen. 2008. Available from: http://www.nektar.com/pdf/pipeline/NKTR-118/NKTR-118_Phase_1_APS_Poster_20080507.pdf [Last accessed 25 March 2009]
- Webster L, Dhar S. NKTR-118 significantly reverses opioid-induced constipation. 2009. Available from: http://www.nektar.com/pdf/pipeline/NKTR-118/Nektar_poster118AAPM.pdf [Last accessed 1 October 2009]
- Odinecs A, Song Y, Harite S, NKTR-118, an oral peripheral opioid antagonist, has low potential for drug-drug interactions. 2011. Available from: http://www.nektar.com/pdf/pipeline/NKTR118/ACCP38thAnnualMeetingPoster141.pdf [Last accessed 9 September 2007]
- Aguiar M. Press release: Theravance Announces Initiation of Proof of Concept Phase 2 Clinical Study with its PUMA Compound, TD-1211, for the Treatment of Opioid-Induced Constipation. 2010. Available from: http://files.shareholder.com/downloads/THERA/838143856x0x365392/f57f50cb-1266-4bb1-817d-38b1bbe2fb66/Theravance_PUMA_Initiate_Phase_2_Press_Release_Final.pdf [Last accessed 25 January 2011]
- Clinicaltrials.gov. 2011. Available from: www.clinicaltrials.gov [Last accessed 25 January 2011]
- Press release: Adolor Corporation initiates clinical testing in opiod bowel dysfunction program. Adolor Corporation. 2009. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=120919&p=irol-newsArticle&ID=1354745&highlight= [Last accessed 25 January 2011]
- Press release: Adolor Corporation initiates phase 2 OIC study of ADL5945. Adolor Corporation. 2010. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=120919&p=irol-newsArticle&ID=1484125&highlight=add%20press%20release [Last accessed 25 January 2011]
- Diego L, Atayee R, Helmons P, Von Gunten CF. Methylnaltrexone: a novel approach for the management of opioid-induced constipation in patients with advanced illness. Expert Rev Gastroenterol Hepatol 2009;3:473-85
- Press release: Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC). Nektar Corporation. 2009. Available from: http://www.nektar.com/pdf/pipeline/NKTR-118/NKTR-118_Phase_2_Results_Press_Release_3.2.09.pdf [Last accessed 25 January 2011]